524 related articles for article (PubMed ID: 29064420)
1. Immunogenomic Classification of Colorectal Cancer and Therapeutic Implications.
Roelands J; Kuppen PJK; Vermeulen L; Maccalli C; Decock J; Wang E; Marincola FM; Bedognetti D; Hendrickx W
Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29064420
[TBL] [Abstract][Full Text] [Related]
2. Novel avenues in immunotherapies for colorectal cancer.
Pardieck IN; Jawahier PA; Swets M; van de Velde CJ; Kuppen PJ
Expert Rev Gastroenterol Hepatol; 2016; 10(4):465-80. PubMed ID: 26582071
[TBL] [Abstract][Full Text] [Related]
3. The correlation between immune subtypes and consensus molecular subtypes in colorectal cancer identifies novel tumour microenvironment profiles, with prognostic and therapeutic implications.
Soldevilla B; Carretero-Puche C; Gomez-Lopez G; Al-Shahrour F; Riesco MC; Gil-Calderon B; Alvarez-Vallina L; Espinosa-Olarte P; Gomez-Esteves G; Rubio-Cuesta B; Sarmentero J; La Salvia A; Garcia-Carbonero R
Eur J Cancer; 2019 Dec; 123():118-129. PubMed ID: 31678770
[TBL] [Abstract][Full Text] [Related]
4. Cross-talk of four types of RNA modification writers defines tumor microenvironment and pharmacogenomic landscape in colorectal cancer.
Chen H; Yao J; Bao R; Dong Y; Zhang T; Du Y; Wang G; Ni D; Xun Z; Niu X; Ye Y; Li HB
Mol Cancer; 2021 Feb; 20(1):29. PubMed ID: 33557837
[TBL] [Abstract][Full Text] [Related]
5. Colorectal Cancer Immune Infiltrates: Significance in Patient Prognosis and Immunotherapeutic Efficacy.
Guo L; Wang C; Qiu X; Pu X; Chang P
Front Immunol; 2020; 11():1052. PubMed ID: 32547556
[TBL] [Abstract][Full Text] [Related]
6. [Going beyond microsatellite instability for immunotherapy in metastatic colorectal cancer: Consensus molecular subtypes and tumor mutational burden].
Cohen R; Heran M; Pudlarz T; Hilmi M; Tournigand C; André T; Rousseau B
Bull Cancer; 2019 Feb; 106(2):151-161. PubMed ID: 30638897
[TBL] [Abstract][Full Text] [Related]
7. The colorectal cancer immune microenvironment and approach to immunotherapies.
Koi M; Carethers JM
Future Oncol; 2017 Aug; 13(18):1633-1647. PubMed ID: 28829193
[No Abstract] [Full Text] [Related]
8. Immunotherapy for colorectal cancer: where are we heading?
Basile D; Garattini SK; Bonotto M; Ongaro E; Casagrande M; Cattaneo M; Fanotto V; De Carlo E; Loupakis F; Urbano F; Negri FV; Pella N; Russano M; Brunetti O; Scartozzi M; Santini D; Silvestris N; Casadei Gardini A; Puzzoni M; Calvetti L; Cardarelli N; Aprile G
Expert Opin Biol Ther; 2017 Jun; 17(6):709-721. PubMed ID: 28375039
[TBL] [Abstract][Full Text] [Related]
9. The clinical implications of immunogenomics in colorectal cancer: A path for precision medicine.
Riley JM; Cross AW; Paulos CM; Rubinstein MP; Wrangle J; Camp ER
Cancer; 2018 Apr; 124(8):1650-1659. PubMed ID: 29315503
[TBL] [Abstract][Full Text] [Related]
10. The Immunogenicity of Colorectal Cancer in Relation to Tumor Development and Treatment.
de Vries NL; Swets M; Vahrmeijer AL; Hokland M; Kuppen PJ
Int J Mol Sci; 2016 Jun; 17(7):. PubMed ID: 27367680
[TBL] [Abstract][Full Text] [Related]
11. A Role for MAIT Cells in Colorectal Cancer.
Berzins SP; Wallace ME; Kannourakis G; Kelly J
Front Immunol; 2020; 11():949. PubMed ID: 32508830
[TBL] [Abstract][Full Text] [Related]
12. Single-cell immune profiling reveals new insights into colorectal cancer.
Lönnberg T; Stubbington MJ
Immunol Cell Biol; 2019 Mar; 97(3):241-243. PubMed ID: 30791147
[No Abstract] [Full Text] [Related]
13. Tumour immune microenvironment biomarkers predicting cytotoxic chemotherapy efficacy in colorectal cancer.
Wilkinson K; Ng W; Roberts TL; Becker TM; Lim SH; Chua W; Lee CS
J Clin Pathol; 2021 Oct; 74(10):625-634. PubMed ID: 33753562
[TBL] [Abstract][Full Text] [Related]
14. [Immune response and colorectal cancer].
Tougeron D; Fauquembergue E; Latouche JB
Bull Cancer; 2013 Mar; 100(3):283-94. PubMed ID: 23501583
[TBL] [Abstract][Full Text] [Related]
15. MicroRNAs: Novel immunotherapeutic targets in colorectal carcinoma.
Li X; Nie J; Mei Q; Han WD
World J Gastroenterol; 2016 Jun; 22(23):5317-31. PubMed ID: 27340348
[TBL] [Abstract][Full Text] [Related]
16. Tumor Microenvironment Remodeling by 4-Methylumbelliferone Boosts the Antitumor Effect of Combined Immunotherapy in Murine Colorectal Carcinoma.
Malvicini M; Fiore E; Ghiaccio V; Piccioni F; Rizzo M; Olmedo Bonadeo L; García M; Rodríguez M; Bayo J; Peixoto E; Atorrasagasti C; Alaniz L; Aquino J; Matar P; Mazzolini G
Mol Ther; 2015 Sep; 23(9):1444-55. PubMed ID: 26105158
[TBL] [Abstract][Full Text] [Related]
17. Current and Prospective Methods for Assessing Anti-Tumor Immunity in Colorectal Cancer.
Nussbaum YI; Manjunath Y; Suvilesh KN; Warren WC; Shyu CR; Kaifi JT; Ciorba MA; Mitchem JB
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946558
[TBL] [Abstract][Full Text] [Related]
18. [Immune response and digestive cancers: Prognostic and therapeutic implications].
Bibeau F; Bazille C; Svrcek M; Pierson R; Lagorce-Pagès C; Cohen R; André T
Ann Pathol; 2017 Feb; 37(1):111-116. PubMed ID: 28111038
[TBL] [Abstract][Full Text] [Related]
19. T cell subsets and colorectal cancer: discerning the good from the bad.
Scurr M; Gallimore A; Godkin A
Cell Immunol; 2012 Sep; 279(1):21-4. PubMed ID: 23041206
[TBL] [Abstract][Full Text] [Related]
20. Colorectal cancer: A paradigmatic model for cancer immunology and immunotherapy.
IJsselsteijn ME; Sanz-Pamplona R; Hermitte F; de Miranda NFCC
Mol Aspects Med; 2019 Oct; 69():123-129. PubMed ID: 31136750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
